Sarepta Therapeutics (SRPT) Prepaid Assets (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Prepaid Assets of $2.2 million for Q1 2026, down 97.9% year-over-year from $105.5 million in Q1 2025, and down 98.71% quarter-over-quarter from $171.9 million in Q4 2025.
Sarepta Therapeutics (SRPT) Prepaid Assets (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Prepaid Assets history runs 17 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Prepaid Assets fell 97.9% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (down 97.9% YoY), while the FY2025 annual figure was $171.9 million, up 89.98% from the prior year.
- Prepaid Assets for Q1 2026 stood at $2.2 million, down from $171.9 million in the prior quarter.
- The five-year high for Prepaid Assets was $179.8 million in Q1 2023, with the low at $2.0 million in Q1 2024.
- The 5-year median for Prepaid Assets is $105.5 million (2025), against an average of $88.7 million.
- The sharpest annual moves came in 2022 and 2024: Prepaid Assets soared 12605.93% in 2022, then plunged 98.91% in 2024.
- Sarepta Therapeutics' Prepaid Assets stood at $149.9 million in 2022, then plunged by 97.76% to $3.4 million in 2023, then surged by 2598.72% to $90.5 million in 2024, then surged by 89.98% to $171.9 million in 2025, then slumped by 98.71% to $2.2 million in 2026.
- Business Quant data shows SRPT's Prepaid Assets at $2.2 million in Q1 2026, $171.9 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 105.78 Mn |
| Mar 31, 2026 | 2.22 Mn |
| Dec 31, 2025 | 171.86 Mn |
| Sep 30, 2025 | 2.41 Mn |
| Jun 30, 2025 | 127.59 Mn |
| Mar 31, 2025 | 105.48 Mn |
| Dec 31, 2024 | 90.46 Mn |
| Sep 30, 2024 | 165.48 Mn |
| Jun 30, 2024 | 74.74 Mn |
| Mar 31, 2024 | 1.95 Mn |
| Dec 31, 2023 | 3.35 Mn |
| Sep 30, 2023 | 154.44 Mn |
| Jun 30, 2023 | 3.14 Mn |
| Mar 31, 2023 | 179.77 Mn |
| Dec 31, 2022 | 149.89 Mn |
| Sep 30, 2022 | 130.74 Mn |
| Jun 30, 2022 | 3.28 Mn |
| Mar 31, 2022 | 140.33 Mn |
| Dec 31, 2021 | 149.03 Mn |
| Sep 30, 2021 | 1.03 Mn |